A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Status:	Recruiting
Conditions:	Colitis, Colitis, Gastrointestinal
Therapuetic Areas:	Gastroenterology
Healthy:	No
Age Range:	18 - 80
Updated:	4/5/2019
Start Date:	July 18, 2018
End Date:	August 23, 2023
Contact:	There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:	ClinicalTrials.gov@lilly.com
Phone:	1-317-615-4559

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

This study designed to evaluate the long-term efficacy and safety of mirikizumab in
participants with moderately to severely active ulcerative colitis (UC).

- Inclusion Criteria

- Participants from Study AMAC (NCT02589665) or AMBG (NCT #:TBD) who have had at
least one study drug administration and have not had early termination of study
drug.

- Female participants must agree to contraception requirements.

- Exclusion Criteria

- Participants must not have developed a new condition, including cancer in the
originator study.

- Participants must not have any important infections including, but not limited
to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during
either originator study

- Participants may not have received surgery for UC in the originator study or are
likely to require surgery for treatment of UC during the study.

- Participants must not have developed adenomatous polyps during the originator
study that have not been removed prior to the start of this study.

We found this trial at

sites

Gastroenterology Research Of San Antonio

San Antonio, Texas 78229

Principal Investigator: Nicholas P Martinez

Phone: 210-615-3848

from

San Antonio, TX